Latest Bicalutamide Stories
Hormonal therapies can help control advanced prostate cancer for a time.
While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50.
Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels.
Androgen suppression – the inhibition of testosterone and other male hormones – is a routine therapy for prostate cancer.
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show.
Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients.
SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
SAN FRANCISCO and TOKYO, Sept. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
SAN FRANCISCO, June 1 /PRNewswire/ -- Prostate cancer patients on leuprolide who were offered to continue on FIRMAGONÂ® (degarelix for injection) after one year of treatment reduced prostate specific antigen (PSA) recurrence, according to results of a Phase III extension study(1) presented here at the American Urological Association 2010 meeting.
SAN DIEGO, April 22 /PRNewswire/ -- Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors and The Column Group.
- A poem in which the author retracts something said in an earlier poem.